Patients prescribed with Apixaban 2.5 mg and 5 mg film-coated tablets from Marketing Authorisation Holder, Silicon Pharma Limited will receive a Patient Alert Card in the medication pack along with the package leaflet. Please ensure you have read and understood the information in the card because it contains important safety information including the importance of taking Apixaban tablets regularly as instructed by your treating Doctor, the main signs and symptoms of bleeding, and when to seek medical attention. Please carry the Patient Alert Card with you at all times and show it to every healthcare professional including pharmacists. Patient Alert Card is approved by MHRA in 11/2025. This is for UK Only additional risk minimisation materials.

This additional risk minimisation material is for Apixaban 2.5 mg and 5 mg film coated tablet from Marketing Authorisation Holder, Silicon Pharma Limited. Please ensure that you are familiar with this material before prescribing Apixaban Tablets as it contains important safety information on the potential risk of bleeding during treatment and provides guidance on how to manage that risk. Prescriber Guide is approved by MHRA in 11/2025. This is for UK Only additional risk minimisation material.